Aim: Zolpidem is a non-benzodiazepine agonist at benzodiazepine binding site in GABA A receptors, which is increasingly prescribed. Recent studies suggest that prolonged zolpidem treatment induces tolerance. The aim of this study was to explore the adaptive changes in GABA A receptors following short and long-term exposure to zolpidem in vitro. Methods: Human embryonic kidney (HEK) 293 cells stably expressing recombinant α1β2γ2s GABA A receptors were exposed to zolpidem (1 and 10 μmol/L) for short-term (2 h daily for 1, 2, or 3 consecutive days) or long-term (continuously for 48 h). Radioligand binding studies were used to determine the parameters of 
Introduction
Gamma-aminobutyric acid type A (GABA A ) receptors are ligand gated ion channels activated physiologically by the main inhibitory neurotransmitter γ-aminobutyric acid (GABA). Functional GABA A receptors are formed by five subunits derived from seven receptor subunit families (a1-6, β1-3, γ1-3, δ, ε, θ, and π). Different subunit isoforms are expressed with regional specificity and in a cell-type specific manner [1] . In the central nervous system, the most common receptor form is comprised of the α1, β2, and γ2 subunits, with a defined stoichiometry of 2α:2β:1γ [2] . Imidazopyridine zolpidem is a non-benzodiazepine hypnotic that exerts its effects via the benzodiazepine binding site on GABA A receptors. Zolpidem has a very high affinity for receptors containing the α1 subunit, has an intermediate affinity for receptors that contain α2 or α3, and does not interact with GABA A receptors consisting of the α5 subunit [3] [4] [5] [6] . In addition to its sedative effects, zolpidem has considerable anticonvulsant activity [7, 8] . Moreover, recent studies provide a rationale for further investigations of its potential in the treatment of basal ganglia disorders [9] . Benzodiazepines are widely used clinically to obtain one of the following major effects: decrease in sleep latency, reduction of anxiety, antiepileptic action or muscle relaxation. They are positive allosteric modulators of GABA A receptors. Benzodiazepines bind to a binding pocket on the α/γ subunit interface. In general, benzodiazepines are safe and effective for short-term treatment. On the other hand, due to the development of tolerance and potential for dependence, the appropriateness of benzodiazepines for long-term use is controversial.
It has been supposed that drugs with a high selectivity for α1 containing receptors have fewer side effects compared to classical benzodiazepines. Although chemically different than benzodiazepines, zolpidem elicited many side effects simi- [10] demonstrated development of anticonvulsant and sedative tolerance after repeated (10 days) zolpidem treatment in mice. Similar results were obtained in rats [11] . Several studies have also suggested that zolpidem has a significant risk of abuse and dependence in humans [12] . In their study, Vlainić and colleagues (2010) [13] showed that a 2-day zolpidem (10 μmol/L) treatment enhances the number of recombinant α1β2γ2s GABA A receptors and produces functional uncoupling between GABA and benzodiazepine binding site. Moreover, the observed changes are not substantially different from those detected after prolonged exposure of these cells to high doses of the classical benzodiazepine, diazepam [14] . Despite of many studies, the molecular mechanisms involved in the development of tolerance to the actions of benzodiazepines remain unknown [15] [16] [17] . The aim of our study was to explore the molecular mechanisms induced by zolpidem treatment using radioligand binding assays.
Materials and methods

Cell culture
The human embryonic kidney (HEK) 293 cell line stably expressing the α1β2γ2 S subtype of GABA A receptor was kindly donated by Dr David GRAHAM (Sanofi-Synthélabo Research, France). The cells were maintained in 75-cm 2 flasks at 37 °C in humidified air with 5% CO 2 according to standard cell culture techniques. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L L-glutamine, 100 units/ mL penicillin and 100 µg/mL streptomycin.
Drugs
Zolpidem [N,N,6-trimethyl-2-(4-methylphenyl)-imidazo(1,2-a) pyridine-3-acetamide] was a generous gift from Pliva (Zagreb, Croatia). [ 3 H]flunitrazepam (specific activity 87 Ci/mmol) was purchased from Amersham Biosciences UK Ltd. Culture medium, antibiotics, fetal bovine serum and other chemicals were supplied from Invitrogen/Gibco (Grand Island, NY, USA).
Drug treatment
Cells were seeded onto new flasks and grown for 3 d prior to exposure to drugs. We had four different treatment regimens:
Continuous zolpidem treatment: on the initial day, the medium was replaced with a fresh medium containing zolpidem (final concentrations 1 and 10 µmol/L) for 48 h in the presence of 1 µmol/L GABA.
Single dose of zolpidem (final concentrations 1 and 10 µmol/L): the medium containing zolpidem was replaced with fresh medium following a 2-h treatment period. The cells were grown in the presence of 1 µmol/L GABA.
Zolpidem treatment for two consecutive days: the medium containing zolpidem (final concentrations 1 and 10 µmol/L) was replaced after a 2-h treatment with fresh medium. The same procedure (treatment/fresh medium) was repeated the next day. The cells were grown in the presence of 1 µmol/L
GABA.
Zolpidem treatment for three consecutive days: zolpidem (final concentrations 1 and 10 µmol/L) was added to the medium for a 2-h treatment period and then replaced with fresh medium. The same procedure was repeated for three consecutive days. The cells were grown in the presence of 1 µmol/L GABA.
Zolpidem and GABA were dissolved in distilled water. The control cells were treated with corresponding vehicle in the presence of 1 µmol/L GABA.
Radioligand binding studies Preparation of the membranes
Membranes from stably transfected HEK 293 cells were prepared mainly as described by Peričić et al (2005) [18] . Briefly, the cells were washed with phosphate-buffer saline (PBS), scraped from the flasks into ice-cold PBS, and centrifuged at 12 000×g for 12 min. The cell pellet was homogenized in 50 mmol/L Tris-citrate buffer at pH 7.4 by 10 strokes (up and down) at 1250 r/min using a teflon pestle and glass homogenizer. The cells were then centrifuged at 200 000×g for 20 min. The same procedure (re-suspension/ centrifugation) was repeated two more times. Finally, the pellet was re-suspended and stored in aliquots at -20 °C. The cell membrane suspension was centrifuged once more on the day of the The radioactivity bound to the membranes was counted on a β-scintillation counter (Perkin Elmer, Wallace 1409DSA) after a rapid vacuum filtration on Whatman GF/C filters.
Using bovine serum albumin as a standard, the protein concentration was determined in 10 µL samples of each membrane suspension.
Statistical analysis
The analysis of binding data was performed using the GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA Statistical evaluation was performed with one-way analysis of variance (ANOVA) followed by a post-hoc NewmanKeuls multiple comparison test. All data are expressed as the mean±SEM of at least three independent experiments performed in duplicate. P-values of less than 0.05 were considered significant.
Results
The effect of long-term zolpidem treatment on The cells were treated with 10 μmol/L zolpidem once for 2 h, or for a 2-h period per day during two or three consecutive days in the presence of 1 μmol/L GABA. As shown in Figure  3 and indicated by one-way ANOVA, there is no significant difference among these groups. The intermittent shortterm zolpidem treatment (2 h once and during two or three consecutive days) did not affect [ Statistical analysis showed no significant change among the groups (ANOVA followed by the Newman-Keuls test). 
Discussion
Recent studies have provided evidence that benzodiazepines share the pharmacological profile of addictive drugs through cell-type specific expression of α1-containing GABA A receptors [13, 14, 19] . Non-benzodiazepine zolpidem acts selectively at α1 subunit-containing GABA A receptors and is considered to be devoid of addiction liability. To test whether zolpidem induces similar molecular changes as those reported to be linked to the development of tolerance, we conducted several experiments. The present results demonstrate that a single It has been shown that a single intra-peritoneal injection of benzodiazepines is sufficient to induce synaptic plasticity in mice. It is postulated that observed early adaptive changes are not sufficient to explain long-term development of addiction. Instead, they represent an imperative initial step that triggers synaptic changes in addiction if the use of drug becomes chronic. Furthermore, it has been shown that benzodiazepine-induced changes in synaptic plasticity depend on α1-containing GABA A receptors because the observed changes are abolished in α1-H101R knock-in mice [19] . In our model, a single dose of zolpidem and short-term intermittent zolpidem treatment did not induce molecular changes at GABA A receptors regarding receptor number and GABA potentiation. This suggests that zolpidem might have a lower propensity for inducing molecular changes at GABA A receptors, possibly associated with the development of tolerance if used in a strict daily regime. On the other hand, as shown recently, long-term continuous occupation of GABA A receptors with zolpidem can induce adaptive changes at GABA A receptors [13] . It should be Statistical analysis showed no significant change among the groups (ANOVA followed by the Newman-Keuls test).
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Acta Pharmacologica Sinica npg mentioned that these changes are not substantially different from those obtained after prolonged exposure of these cells to high doses of classical benzodiazepine-diazepam [14, 20] . Moreover, [13] assumed that prolonged zolpidem treatment induces an increase of cell-surface GABA A receptors that are functionally active. Several potential mechanisms could underlie the up-regulation of GABA A receptor number: an increased synthesis, a decreased degradation of receptor proteins or an enhanced rate of receptor incorporation into membranes. The same authors also showed an increased level of α1 subunit mRNA and γ2 subunit proteins suggesting at least a partial role of transcriptional mechanisms in zolpideminduced enhancement of GABA A receptors. Although mRNA changes do not necessarily reflect changes in protein expression [21, 22] , Uusi-Oukari et al (2000) [1] showed that there is tight control between the expression of α1 subunit mRNA and polypeptide. Moreover, it has been demonstrated that benzodiazepines regulate α1 [23] and γ2 [24] subunit mRNA at the level of transcription. A general trophic effect of zolpidem treatment on the growth of HEK 293 cells could presumably be excluded because total cellular proteins did not vary between the control and zolpidem-pre-treated group (data not shown).
Furthermore, 2-d zolpidem treatment produced functional uncoupling between the GABA and benzodiazepine binding sites, as demonstrated by the study of Primus et al (1996) [25] . The functional consequences of zolpidem-induced augmentation of GABA A receptor number observed in the study along with the reduced functional coupling were not determined. The exact molecular mechanism(s) leading to functional uncoupling between GABA and benzodiazepine binding sites remain unknown. Although uncoupling of the benzodiazepine and GABA binding sites could be produced by drugs inhibiting protein kinase A, it is supposed that direct phosphorylation of GABA A receptors is not involved in coupling/ uncoupling processes [26] . The same authors proposed that prolonged benzodiazepine treatment induces internalization of surface GABA A receptors into intracellular vesicles, where the potentiation by GABA is impaired but the normal benzodiazepine binding can occur. However, several studies [20, 25] have failed to support the internalization model of GABA A receptors. The observed reduction in functional coupling between GABA and benzodiazepine binding sites could represent a conformational change at the receptor binding sites. It has been suggested that residues in and surrounding benzodiazepine binding site are aligned with the residues that form the GABA binding site [27] . Morlock and Czajkowski (2011) [28] speculated that the positioning of the drug at the benzodiazepine binding site and/or the positioning of nearby residues induces different downstream allosteric rearrangements. Thus, allosteric uncoupling between GABA and benzodiazepine binding sites leads to a reduced potency of benzodiazepines. One cannot conclude that zolpidem-mediated activity in animals and humans will be reduced because prolonged zolpidem treatment produced an increase in GABA A receptor number. However, long-term administration of non-selective full positive allosteric modulator of GABA action at GABA A receptors leads to alterations in receptor expression and/or function, resulting in the development of tolerance and dependence. Many authors working either on animals [29] , neuronal cultures [30] [31] [32] or recombinant receptors [13, 14, 20, 25, 26, 33, 34] have found reduced allosteric linkage between GABA and benzodiazepine binding sites as a result of prolonged benzodiazepine action. Moreover, animals and humans treated for prolonged period of time with drugs acting as full positive modulators of GABA action at GABA A receptors developed tolerance characterized by a decreased ability of the drug to produce its pharmacological effect. Although it appears that allosteric uncoupling could explain the development of tolerance, the molecular mechanisms are rather more complex [15, 17] . In conclusion, it should be mentioned that zolpidem, which is highly selective for α1 subunit of GABA A receptors and is claimed to carry a low risk for addiction during long-term treatment, induces adaptive changes that are rather similar to those produced by long-term benzodiazepine treatment. Previous studies on mice [10] and rats [11] suggested that, upon repeated treatment, zolpidem produced tolerance to its anticonvulsive and sedative effects. Therefore, zolpidem has a higher abuse potential than previously suggested [12] . Since 2002, the World Health Organization has considered the frequency of zolpidem abuse and dependence to be similar to that of benzodiazepines.
Our results on intermittent short-term exposure suggest that, if used in a strong daily regime, zolpidem does not produce changes at recombinant GABA A receptors stably expressed in HEK 293 cells. This could presumably be associated with the development of tolerance, as it is with the continuous treatment [13, 35] . The observed changes are not substantially different from those obtained after prolonged exposure of cells to high doses of classical benzodiazepines [14] .
